674289-55-5

674289-55-5 structure

Name: (S)-(-)-Blebbistatin
Chemical Name: blebbistatin
CAS Number: 674289-55-5
Molecular Formula: C₁₈H₁₆N₂O₂
Molecular Weight: 292.332
Catalog: Signaling Pathways Cytoskeleton Myosin
Create Date: 2018-12-08 12:51:04
Modify Date: 2024-01-09 20:31:20
Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function[1].

Name	blebbistatin
Synonyms	(−)-Blebbistatin (+/-)-Blebbistatin (3aS)-3a-Hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one Blebbistatin 4H-Pyrrolo[2,3-b]quinolin-4-one, 1,2,3,3a-tetrahydro-3a-hydroxy-6-methyl-1-phenyl-, (3aS)- (S)-Blebbistatin 3a-hydroxy-6-methyl-1-phenyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one

Description	Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function[1].
Related Catalog	Signaling Pathways >> Cytoskeleton >> Myosin Research Areas >> Others
Target	Non-muscle myosin II (NMII)[1]
In Vitro	The therapeutic potential of targeting NMII to enhance CEC migration is investigated using bovine corneal endothelial cells (BCECs). Blebbistatin, a direct myosin motor inhibitor, promotes migration and directional persistence in CECs through decreasing actin retrograde flow and increasing lamellipodial protrusion persistence to accelerate wound healing in vitro[1].
In Vivo	Blebbistatin (0.05 mL, 20 μM; intracameral injection; daily; for 6 days; New Zealand white rabbits) treatment promotes wound healing in rabbit corneal endothelial scraping model[1]. Animal Model: New Zealand white rabbits (16-20 weeks; 3-3.5 kg) with injected xylazine 5 mg/kg and ketamine 40 mg/kg[1] Dosage: 0.05 mL; 20 μM Administration: Intracameral injection; daily; for 6 days Result: Resulted in significant improvement of corneal clarity and corneal edema resolution, implying the restoration of an intact corneal endothelial monolayer.
References	[1]. Ho WT, et al. Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics. J Mol Med (Berl). 2019 Sep;97(9):1345-1357.